US/UK/Canada

Share

Contacts

  • Pål Ryfors

    CEO


    Karlavägen 60, 114 49 Stockholm
    0709623669
    http://www.episurf.com
    • Pick a time period -
    Tags ( Active)

    The Board of Directors of Episurf has resolved on an issue of Class B shares, convertibles and warrants as part of the consideration for the acquisition of property assets

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR DISCLOSURE WOULD BE IN VIOLATION OF APPLICABLE LAWS OR REQUIRE ADDITIONAL REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. The Board of Directors of Episurf Medical AB (publ) ("Episurf" or

    Episurf Medical acquires a portfolio of four properties in Uppsala with an agreed property value of SEK 300 mn from Setune

    Episurf Medical AB (publ) (Nasdaq: EPIS B) has entered into an agreement to acquire a portfolio of light warehouse and office properties from Setune Assets AB. The agreed property value amounts to SEK 285.5 mn, corresponding to a gross property value of SEK 300 mn before customary deduction for deferred tax. The acquisition brings the Company a portfolio with rental income of approximately SEK 22 mn per year and a net operating income (NOI) of approximately SEK 17.5 mn. Closing is conditional on financing and is expected to occur no later than 1 November 2026. “Through the acquisition

    Episurf Medical acquires properties in Borås

    Episurf Medical AB (publ) (Nasdaq: EPIS B) has entered into an agreement to acquire all shares in HanssonGruppen Räveskalla AB. The acquisition comprises two properties in Räveskalla, Borås, with a total lettable area of 1,735 sqm, and strengthens the Company’s property portfolio with fully let light-industrial premises generating stable cash flows.The acquisition in brief · Two properties in Räveskalla, Borås (Räveskalla 1:435 and Räveskalla 1:506), with a total lettable area of 1,735 sqm. · Agreed property value of SEK 12 mn after deduction of deferred tax. · Fully let with a

    Bulletin from Annual General Meeting in Episurf Medical AB (publ)

    Episurf Medical AB (publ) has held an Annual General Meeting (the "Meeting") on Monday, 25 May 2026. The Meeting resolved in all parts in accordance with the Board of Directors' and the Nomination Committee's proposals.Adoption of the income statement and the balance sheet The Meeting adopted the income statement and the balance sheet of the parent company and the group for the financial year 2025. Dividend The Meeting resolved that no dividend is to be distributed for the financial year 2025. Board of Directors The Meeting discharged the members of the Board of Directors and

    Correction: Missing MAR label in previous press release – Interim Report 1 January – 31 March 2026

    Episurf Medical AB (publ) (Nasdaq: EPIS B) issues a correction of the press release published earlier today. The correction relates to the press release missing the MAR label with reference to the EU Market Abuse Regulation (MAR). In all other respects the press release is unchanged. The following information should have been included in the press release: “This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set

    Interim Report 1 January – 31 March 2026

    Episurf Medical AB (publ) (Nasdaq: EPIS B) today publishes its interim report for the period 1 January – 31 March 2026. The first quarter marked the beginning of the company’s transformation into a cash flow-oriented property company, with the first property acquisitions completed at an underlying property value of approximately SEK 270m. “The first quarter of 2026 marked the beginning of Episurf’s transformation into a cash flow-oriented property company. During the quarter, property acquisitions were completed at an underlying property value of approximately SEK 270m, constituting the

    Episurf Medical acquires a real estate portfolio with an agreed property value of SEK 660m from Lilium

    Episurf Medical AB (publ) (Nasdaq: EPIS B) has entered into an agreement to acquire a portfolio of vehicle inspection and logistics properties from Lilium AB. The agreed property value amounts to SEK 660m. The acquisition adds to the Company a portfolio of vehicle inspection and logistics properties with rental income of approximately SEK 49m per year and a net operating income of approximately SEK 41m. “The Lilium acquisition is another step in building our real estate platform. The Lilium acquisition expands our exposure to industrial properties and adds a portfolio with strong cash flow

    Episurf Medical strengthens its organisation with a Deputy CEO, Christian Oloffson, and Head of Property Management, Petra Widén Lindh

    Episurf Medical AB (publ) (Nasdaq: EPIS B) has appointed Christian Olofsson as Deputy CEO and Head of Business Development and Petra Widén Lindh as Head of Property Management. The recruitments are a strategically important step in the Company’s continued build-up of a broad and cash-flow-generating property platform.Christian Olofsson, Deputy CEO and Head of Business Development Christian Olofsson takes up the role of Deputy CEO and Head of Business Development, with responsibility for analysis, transactions and valuations. Christian has nearly 20 years of experience in the property

    Episurf Medical has completed the acquisition of the property portfolio from Mofast AB

    Episurf Medical AB (publ) (Nasdaq: EPIS B) today completed the acquisition of the property portfolio of 36 social infrastructure properties from Mofast AB (publ), with an agreed property value of approximately SEK 697 mn.All conditions to closing have been satisfied, including approval from the senior lender and a decision from the Swedish Inspectorate of Strategic Products (ISP). The acquisition is financed by a major Nordic bank. The B shares constituting part of the consideration to the seller will be issued following Episurf's annual general meeting on 25 May 2026, and before the end

    Episurf Medical acquires property portfolio with an agreed property value of SEK 845 mn from Botrygg

    Episurf Medical AB (publ) (Nasdaq: EPIS B) has entered into an agreement to acquire a diversified property portfolio from Botrygg in Linköping. Closing will occur once required bank financing has been secured, but no later than 31 October 2026. The agreed property value amounts to SEK 845 mn. The acquisition brings the Company a portfolio of modern community properties with rental income of approximately SEK 67 mn per year and a net operating income (NOI) of approximately SEK 54 mn. “We are pleased to have signed this agreement with Botrygg. Linköping is a strong market and the

    Episurf Medical has entered into letters of intent to acquire four real estate portfolios with a combined agreed property value of approximately SEK 2.6 billion

    Episurf Medical AB (publ) (Nasdaq: EPIS B) ("Episurf" or the "Company") has entered into letters of intent to acquire four portfolios of real estate assets with a combined agreed property value of approximately SEK 2.6 billion. The portfolios comprise light industrial, residential, and community properties located in Sweden. Preliminary signing and completion of all portfolios are expected to take place during the second and third quarters of 2026.Overview The acquisitions comprise a total of approximately 90 properties with a combined lettable area of approximately 150,000 square metres.

    Change in number of shares and votes in Episurf Medical

    As a result of, in accordance with previously announced information, the directed issue of 1,200,000,000 Class B shares resolved on 17 April 2026 and the directed issue of an additional number of 375,466,222 Class B shares resolved on 23 April 2026, the number of shares and votes in Episurf Medical AB (publ) (“Episurf”) has changed.Through the above-mentioned changes, the total number of shares in Episurf amounts to 4,385,960,612, of which 473,357 are Class A shares and 4,385,487,255 are Class B shares, and the total number of votes in Episurf amounts to 4,386,907,326. For further

    The Board of Directors of Episurf has resolved on an issue of Class B shares as part of the consideration for the acquisition of real estate assets

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR DISCLOSURE WOULD BE IN VIOLATION OF APPLICABLE LAWS OR REQUIRE ADDITIONAL REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. The Board of Directors of Episurf Medical AB (publ) ("Episurf" or

    Notice convening the Annual General Meeting of Episurf Medical AB (publ)

    The shareholders of Episurf Medical AB (publ), reg. no. 556767-0541 ("Episurf" or the "Company"), are hereby given notice to attend the Annual General Meeting to be held on Monday, 25 May 2026, at 15.00 (CEST) at Episurf's office at Karlavägen 60, SE-114 49 Stockholm, Sweden. The entrance opens at 14.30 (CEST). The Board of Directors has, pursuant to Chapter 7, Section 4 a of the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)) and the Company's articles of association, resolved that shareholders shall be able to exercise their voting rights by post prior to the Annual General

    Episurf Medical initiates dual-track process for its medtech operations

    Episurf Medical AB (publ) today announced that its board of directors has resolved to initiate a strategic review of the Company’s medtech operations, with the aim of evaluating alternatives to unlock long-term shareholder value. The Company will run a dual-track process with the aim of a full separation of the operations from the Group. “The board has concluded that both the real estate platform and the medtech operations are best positioned to realize their full potential within dedicated structures, each with a clear ownership focus and capital allocation suited to its specific needs. A

    Episurf Medical Acquires Property Portfolio with an Agreed Property Value of SEK 697 Million from Mofast AB

    Episurf Medical AB (publ) (Nasdaq: EPIS B) has entered into an agreement to acquire a portfolio consisting of 36 properties, primarily LSS housing facilities, with a total agreed property value of approximately SEK 697 million. The acquisition is carried out through Episurf acquiring all shares in Bolaget XX22 AB and its wholly-owned subsidiary Mofast Invest II AB and indirect subsidiaries from Mofast AB (Publ), thereby further strengthening the Company’s real estate initiative with a diversified portfolio of social infrastructure properties with stable rental income.“The Mofast acquisition

    Episurf Medical AB’s 2025 annual report is now available

    Episurf Medical’s annual report for 2025 is available as of today at the company’s website, www.episurf.com.   Episurf Medical has of environmental and cost reasons chosen not to print the annual report. A printed version of the annual report will be distributed to shareholders and others who made such request. The annual report can also be ordered from Episurf Medical on the following address: Episurf Medical AB, Karlavägen 60, 114 49 Stockholm, Sweden or by email: ir@episurf.com.  For further information, please contact:  Jens Andersson, CEO, Episurf Medical  Email: jens.

    Notice of Extraordinary General Meeting of Episurf Medical AB (publ)

    The shareholders in Episurf Medical AB (publ), 556767-0541 ("Episurf" or the "Company"), are hereby summoned to the Extraordinary General Meeting (the "Meeting") on 13 April 2026, at 15:00 (CEST) at the Company’s office at Karlavägen 60, SE-114 49 Stockholm, Sweden. Entry and registration begin at 14:30 (CEST). The Board of Directors has, pursuant to Chapter 7, Section 4 a of the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)) and the Company’s Articles of Association, resolved that shareholders shall be able to exercise their voting rights by post prior to the Meeting. Accordingly,

    Episurf Medical changes date for Annual General Meeting and financial reporting

    Episurf Medical (Nasdaq: EPIS B) has today decided to change the date of the Annual General Meeting 2026 as well as the publication dates for the interim report for January–March 2026 and the Annual Report for 2025. The publication of the Annual Report for 2025 is rescheduled from 6 March 2026 to 20 March 2026. The Annual General Meeting 2026 is rescheduled from 10 April 2026 to 25 May 2026. The interim report for the period January–March 2026 is rescheduled from 24 April 2026 to 25 May 2026. An updated financial calendar will be available on the company’s website. For

    Change in number of shares and votes in Episurf Medical

    As a result of, in accordance with previously announced information, the exercise of 450,494,390 warrants of series TO14 B for subscription of the same number of new Class B shares, as well as the directed issue of 700,238,622 Class B shares, the number of shares and votes in Episurf Medical AB (publ) ("Episurf") has changed. Through the above-mentioned changes, the total number of shares in Episurf amounts to 2,810,494,390, of which 473,357 are Class A shares and 2,810,021,033 are Class B shares, and the total number of votes in Episurf amounts to 2,811,441,104. For further

    New US patent approval for Episurf Medical

    Episurf Medical (NASDAQ: EPIS B) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent. The patent, entitled “Metatarsal implant”, relates to the big toe implant that the company has developed. This is the first approval within this patent family. “This patent gives us protection in the US within the field of implants for the metatarsal bone of the toe. This relates to the Episealer® MTP implant for the big toe that the company has developed, a product that is currently undergoing a review process at the US FDA. We are delighted to

    The Board of Directors of Episurf has resolved on an issue of Class B shares, convertible debentures and warrants as part of the consideration for the acquisition of real estate assets

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR DISCLOSURE WOULD BE IN VIOLATION OF APPLICABLE LAWS OR REQUIRE ADDITIONAL REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. The Board of Directors of Episurf Medical AB (publ) ("Episurf" or

    Episurf Medical AB announces outcome of exercise of warrants of series TO14 B

    THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, ISRAEL, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION “IMPORTANT

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media